Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 1.59B |
| Revenue (ttm) | 224.00M |
| Net Income (ttm) | -158.56M |
| Shares Out | 47.13M |
| EPS (ttm) | -3.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 366,585 |
| Open | 34.18 |
| Previous Close | 34.16 |
| Day's Range | 33.45 - 34.52 |
| 52-Week Range | 23.14 - 35.56 |
| Beta | 1.10 |
| Analysts | Strong Buy |
| Price Target | 53.54 (+58.97%) |
| Earnings Date | Aug 1, 2024 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2023, MIRM's revenue was $186.37 million, an increase of 141.85% compared to the previous year's $77.06 million. Losses were -$163.42 million, 20.5% more than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price forecast is $53.54, which is an increase of 58.97% from the latest price.
News
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #CTX--Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX.
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies
Monday, Mirum Pharmaceuticals Inc. MIRM announced interim results from two Phase 2b studies evaluating volixibat for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pbc--Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies.
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference.
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months and Older.
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #PFIC--Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress.
Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals' LIVMARLI Data Showcased at ESPGHAN Annual Meeting.
Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update.
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference.
Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pfic--Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC.
Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2024 financial results on May 8, 2024. Mirum will also host a confere...
Mirum Pharmaceuticals' LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum's LIVMARLI Receives Positive Reimbursement Recommendation by Canada's CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome.
US FDA approves expanded use of Mirum's liver disease drug
The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the company sa...
Mirum Pharmaceuticals' LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #pfic--Mirum's LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the...
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update.
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024.
Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #leadership--Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer.
Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates.
Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference.
Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia.
Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference.
Mirum Pharmaceuticals Presents New Data at The Liver Meeting®
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Pharmaceuticals Presents New Data at The Liver Meeting®.